Supergut shines in Ozempic era: 'We've tripled the business over the past 5-6 months'

Is Ozempic “an existential threat to the processed food industry,” as one academic recently told the New York Times, or is it creating new opportunities for creative food marketers and formulators?
One company capitalizing on a surge of consumer interest in natural alternatives to GLP-1 drugs is Supergut (formerly Muniq), a startup making bars and shakes containing a blend of resistant starches and prebiotic fibers that are fermented in the gut to produce short chain fatty acids. These in turn are claimed to stimulate production of GLP-1, the gut hormone associated with satiety that Ozempic-like drugs are mimicking.
At the Future Food-Tech conference in San Francisco, AgFunderNews caught up with founder and CEO Marc Washington, who started pitching his wares as ‘Nature’s Ozempic’ a few months ago (a claim some legal experts have urged food brands to avoid) and has seen his business triple.